Related Experiment Video
Updated: Jul 3, 2026
13:26
Determination of Protein-ligand Interactions Using Differential Scanning Fluorimetry
Published on: September 13, 2014
Regulation of hexokinase binding to VDAC
1Department of Molecular Biology, University of Medicine and Dentistry of New Jersey, Science Center, Stratford, NJ 08084, USA. pastorjg@umdnj.edu
Journal of Bioenergetics and Biomembranes
|August 7, 2008
Summary
Hexokinase II binds to mitochondria, suppressing apoptosis and aiding tumor growth. This interaction with VDAC may be a target for cancer therapy by modulating cell death pathways.
Area of Science:
- Cellular Biology
- Biochemistry
- Cancer Research
Background:
- Hexokinase isoforms I and II bind to mitochondrial outer membranes via voltage-dependent anion channel (VDAC).
- This binding influences mitochondrial susceptibility to apoptosis, mediated by Bcl2-family proteins.
- Hexokinase II upregulation in tumors offers metabolic advantages and chemoresistance, but its anti-apoptotic mechanisms are unclear.
Purpose of the Study:
- To investigate the hypothesis that hexokinase competes with Bcl2 proteins for VDAC binding.
- To elucidate the regulatory mechanisms of hexokinase-VDAC interaction.
- To understand the role of hexokinases in cancer treatment optimization.
Main Methods:
- The study focuses on the competitive binding hypothesis between hexokinase and Bcl2 proteins at the VDAC.
- Investigates regulation by protein kinases like GSK-3beta and PKC-epsilon.
- Examines the potential role of mitochondrial membrane cholesterol content and VDAC-associated proteins.
Main Results:
- Hexokinase binding to VDAC is proposed to shift the balance of pro- and anti-apoptotic proteins.
- Protein kinases (GSK-3beta, PKC-epsilon) and mitochondrial cholesterol are implicated in regulating hexokinase-VDAC interaction.
- VDAC-associated proteins are involved in cholesterol uptake, potentially influencing hexokinase binding.
Conclusions:
- Hexokinase binding to VDAC is a key regulator of mitochondrial apoptosis.
- Understanding these regulatory mechanisms is crucial for cancer therapy.
- Targeting hexokinase-VDAC interactions could offer novel strategies for cancer treatment.
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:08Allosteric Regulation
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
01:08Allosteric Regulation
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
02:04Covalently Linked Protein Regulators
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein.
These groups modify specific amino acids in a protein.
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
00:49Ligand Binding and Linkage
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence the...